In another misstep for Vivus, FDA's promo police ding misleading Qsymia webpage

FDA Building 2
The FDA's drug promotions enforcement arm issued its second letter of the year, nicking Vivus for misleading claims online. (FDA)

In just its second enforcement letter this year, the FDA's Office of Prescription Drug Promotion clamped down on Vivus for a webpage marketing its struggling obesity drug Qsymia. 

 

On the offending page, Vivus offered misleading messages and omitted key information about Qsymia, the untitled letter said. OPDP cited claims that the obesity drug “can help you lose weight three times faster than diet and exercise.” Although Vivus drew the claims from the drug's clinical data, those results do not support a particular rate of weight loss, the letter said. The FDA also dinged Vivus for omitting the “material information” that Qsymia is approved only as an add-on to diet and exercise.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Pharma ad police issues 2019's first warning over promotion of unapproved imaging drug

Vivus has already changed the website—the OPDP letter went out May 22—swapping the “three times faster” claim for a more subdued one. “Extensively studied and prescribed, Qsymia is the once-daily pill that helps you manage your weight-loss plan and set realistic expectations," the revised page states.

Speaking of realistic expectations, Qsymia has fallen far short of early sales hopes. The obesity treatment, approved to much fanfare in 2012, failed to gain traction early on thanks to stubborn payers, skeptical doctors and a cloud of worries lingering after past diet-drug scares.

By 2015, with sales still lagging and an FDA-mandated—and pricey—cardiovascular safety study hanging over its head, Vivus slashed jobs and cut costs. Its salesforce cutbacks didn't make it any easier to promote the med, exacerbating a controversial decision from the company to go without a Big Pharma marketing partner. Though execs touted plans to play up digital media to account for less detailing, by 2018, Qsymia was pulling in just $40.6 million in annual sales, a 10% decrease from the previous year. 

RELATED: Flailing Vivus halves hard-hit Qsymia sales force as revenue lags

The Vivus letter is only OPDP’s second of the year, following an earlier warning to Phoenix Molecular Imaging Center for jumping the gun by suggesting its investigational drug Sodium Acetate C-11 is safe and effective for a purpose that's still under study.

The OPDP has slowed down on warning and untitled letters to pharma in recent years, averaging fewer than 10 letters annually since 2014.

Both letters address misleading claims and the omission of risk information, which may indicate the OPDP is concentrating on those areas, said Eye on FDA blogger and public relations professional Mark Senak, in a recent post.

“By OPDP standards, the year is still young, and it is possible we could see more letters this year, but look for them in areas of risk information and promotion of an unapproved drug or use,” he said.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.